Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Antengene Licenses ATG-201 to UCB in $1.1B+ Deal – CD19/CD3 T‑Cell Engager Targets Autoimmune Diseases

Fineline Cube Mar 4, 2026
Company Deals

Sino Biopharma Licenses Rovadicitinib to Sanofi in $1.53B Deal – First‑in‑Class JAK/ROCK Inhibitor Goes Global

Fineline Cube Mar 4, 2026
Company Deals Medical Device

Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market

Fineline Cube Mar 3, 2026
Company Deals

Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy

Fineline Cube Mar 3, 2026
Company Deals

ArkBio Partners with Qilu Pharma on Azstarys China Commercialization – ADHD Therapy Market Entry

Fineline Cube Mar 3, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Deals Drug

Antengene Licenses ATG-201 to UCB in $1.1B+ Deal – CD19/CD3 T‑Cell Engager Targets Autoimmune Diseases

Fineline Cube Mar 4, 2026
Company Drug

ImmuneOnco’s IMM0306S Wins NMPA Approval – Subcutaneous CD47×CD20 Bispecific for Lupus Enters Clinic

Fineline Cube Mar 4, 2026
Company Drug

Sinocelltech Granted NMPA Approval for Phase I Clinical Trial in Hematological Malignancies

Fineline Cube Jan 19, 2024

Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has announced that it...

Company Drug

Sanofi’s Dupixent Receives FDA Label Update for Atopic Dermatitis Patients with Hand or Foot Involvement

Fineline Cube Jan 19, 2024

Sanofi (NASDAQ: SNY) has been granted authorization by the US Food and Drug Administration (FDA)...

Company Drug

Luzhu Biotechnology’s LZ901 Herpes Zoster Vaccine Trial Fully Enrolls 26,000 Participants

Fineline Cube Jan 19, 2024

Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a leading manufacturer of human vaccines and therapeutic...

Company Deals

Danaher Corporation to Establish Northern China Headquarters in Beijing’s Changping District

Fineline Cube Jan 19, 2024

The Changping District People’s Government of Beijing Municipality has entered into a strategic cooperation agreement...

Company Deals

Glorious Med and Illumina Join Forces for Advanced Urinary Tract Infection Detection

Fineline Cube Jan 19, 2024

Hangzhou-based Glorious Med, a premier company specializing in gene detection for urinary system tumors, has...

Company Drug

CARsgen Therapeutics’ CT041 Shows Promising Results in Advanced Solid Tumors at ASCO GI 2024

Fineline Cube Jan 19, 2024

China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the presentation of...

Company Medical Device

Ultrasound Biotechnology Earns FDA Nod for Disposable Endoscopic Ultrasound Probes

Fineline Cube Jan 19, 2024

Ultrasound Biotechnology, the Shanghai-based wholly owned subsidiary of US firm Ultrasound Wondering, Inc., has announced...

Company Deals Digital

Meinian Onehealth Collaborates with Huawei Cloud and Runda Medical on AI Health Robot

Fineline Cube Jan 19, 2024

Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a strategic partnership with...

Company Deals

Sinovac Biotech Ltd Dismisses UK Private Equity’s Nominal Share Acquisition Offer

Fineline Cube Jan 19, 2024

Sinovac Biotech Ltd (NASDAQ: SVA) has released a statement declaring that its board of directors...

Company Drug

Beijing Aosaikang Initiates Phase III Trial for Advanced Gastric Cancer Treatment

Fineline Cube Jan 18, 2024

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has registered a Phase...

Company Deals R&D

Zhejiang Dian Diagnostics Partners with Gulf Medical University for Middle East Expansion

Fineline Cube Jan 18, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a Chinese diagnostics company, has entered into a...

Company Drug

FDA Approves Casgevy, the First CRISPR-Based Gene Editing Therapy for β-Thalassemia

Fineline Cube Jan 18, 2024

Casgevy (exagamglogene autotemcel), the pioneering gene editing therapy based on CRISPR technology, has received approval...

R&D

Sun Yat-sen University Researchers Develop AI Model for Early Ovarian Cancer Detection

Fineline Cube Jan 18, 2024

Researchers at Guangzhou’s Sun Yat-sen University Cancer Center have made a significant breakthrough with the...

Company Drug

Shanghai-Based NK CellTech Earns FDA IND Clearance for Non-Genetically Modified NK Cell Therapy

Fineline Cube Jan 18, 2024

NK CellTech, a Shanghai-based developer of NK cell therapies, has announced that it has received...

Policy / Regulatory

Hainan Province Unveils Measures to Support Innovative Drugs and Medical Devices Development

Fineline Cube Jan 18, 2024

Hainan provincial bureaus, including the Healthcare Security Administration (HSA), Healthcare Commission, and Medical Products Administration,...

Legal / IP Policy / Regulatory

Shanghai Medical Products Administration Issues Trial Measures for Pharmaceutical Quality and Safety Personnel

Fineline Cube Jan 18, 2024

The Shanghai medical products administration has released the “Measures for the Management of Key Quality...

Company Legal / IP

USPTO Invalidates Key Seagen-Held Patent in ADC Conjugation Dispute with Daiichi Sankyo

Fineline Cube Jan 18, 2024

In a surprising turn of events in the ongoing intellectual property dispute, the US Patent...

Company

Bayer Unveils New Operating Model to Drive Profitable Growth Amid Challenges

Fineline Cube Jan 18, 2024

Facing a challenging business landscape, Germany’s Bayer (ETR: BAYN) has announced a new operating model...

Company Drug

Eisai and Medivir’s Combo Therapy Advances in Liver Cancer with Positive Trial Results

Fineline Cube Jan 18, 2024

Japanese pharmaceutical company Eisai’s (TYO: 4523) kinase inhibitor Lenvima (Lenvatinib), combined with Swedish partner Medivir’s...

Legal / IP Policy / Regulatory

Shanghai Enhances Biomedicine IP Protection with New Procurement-Linked Measures

Fineline Cube Jan 18, 2024

The Shanghai Intellectual Property Administration (SIPA) has issued a notification highlighting the city’s intensified efforts...

Posts pagination

1 … 376 377 378 … 629

Recent updates

  • Antengene Licenses ATG-201 to UCB in $1.1B+ Deal – CD19/CD3 T‑Cell Engager Targets Autoimmune Diseases
  • Sino Biopharma Licenses Rovadicitinib to Sanofi in $1.53B Deal – First‑in‑Class JAK/ROCK Inhibitor Goes Global
  • ImmuneOnco’s IMM0306S Wins NMPA Approval – Subcutaneous CD47×CD20 Bispecific for Lupus Enters Clinic
  • MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions
  • Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Antengene Licenses ATG-201 to UCB in $1.1B+ Deal – CD19/CD3 T‑Cell Engager Targets Autoimmune Diseases

Company Deals

Sino Biopharma Licenses Rovadicitinib to Sanofi in $1.53B Deal – First‑in‑Class JAK/ROCK Inhibitor Goes Global

Company Drug

ImmuneOnco’s IMM0306S Wins NMPA Approval – Subcutaneous CD47×CD20 Bispecific for Lupus Enters Clinic

Medical Device

MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.